Cancer Cachexia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major cancer cachexia markets are expected to exhibit a CAGR of 3.77% during 2024-2034.
The cancer cachexia market has been comprehensively analyzed in IMARC's new report titled "Cancer Cachexia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cancer cachexia is a complex and debilitating condition that commonly occurs in individuals with cancer. It is characterized by progressive weight loss, muscle wasting, and loss of appetite, despite adequate food intake. Cachexia is more prevalent in advanced stages of cancer and can significantly impact a patient's quality of life, treatment response, and overall prognosis. While the precise mechanisms underlying cancer cachexia are not entirely comprehended, its development is influenced by various factors. These factors include the release of pro-inflammatory cytokines (small proteins involved in cell signaling), metabolic changes induced by tumors, and the body's reaction to the presence of cancer cells. The diagnosis of cancer cachexia involves a medical history and physical examination, body weight and BMI, laboratory tests, and imaging tests. The treatment involves nutritional support, appetite stimulants, physical activity, and palliative care.
The increasing prevalence of cancer and cachexia, especially amongst the rising geriatric populations, is facilitating the demand for advanced therapeutic treatment and drugs, which in turn, is primarily driving the market growth. This is further supported by the increasing awareness amongst consumers regarding the availability of novel therapeutic drugs to treat cancer cachexia. Additionally, the shifting inclination of patients toward combinational therapies for improving lean body mass (LBM) through pharmacological, and non-pharmacological therapies and clinical trials is acting as another growth-inducing factor Moreover, significant technological advancements that are emphasizing on the development of effective medicines for cancer cachexia treatment are further propelling the market growth. Apart from this, the numerous favorable initiatives being undertaken by the government bodies of various countries and non-governmental organizations (NGOs) for sensitizing people regarding the causes of cancer cachexia, their symptoms, and the benefits of using advanced treatments are creating a positive outlook for the market.
IMARC Group's new report provides an exhaustive analysis of the cancer cachexia market in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets.
According to the report, the United States has the largest patient pool for cancer cachexia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cancer cachexia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cancer cachexia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cancer cachexia market
Reimbursement scenario in the market
In-market and pipeline drugs
Cancer Cachexia - In-Market and Pipeline Drugs
This report also provides a detailed analysis of the cancer cachexia disease marketed drugs and late-stage pipeline drugs.
In-cancer cachexia Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline cancer cachexia disease Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Regulatory Status
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the cancer cachexia market performed so far and how will it perform in the coming years?
What are the market shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cancer cachexia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cancer cachexia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cancer cachexia across the seven major markets?
What is the number of prevalent cases (2018-2034) of cancer cachexia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cancer cachexia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with cancer cachexia across the seven major markets?
What is the size of the cancer cachexia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cancer cachexia?
What will be the growth rate of patients across the seven major markets?
Cancer Cachexia: Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cancer cachexia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cancer cachexia market?
What are the key regulatory events related to the cancer cachexia market?
What is the structure of clinical trial landscape by status related to the cancer cachexia market?
What is the structure of clinical trial landscape by phase related to the cancer cachexia market?
What is the structure of clinical trial landscape by route of administration related to the cancer cachexia market?
The cancer cachexia market has been comprehensively analyzed in IMARC's new report titled "Cancer Cachexia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cancer cachexia is a complex and debilitating condition that commonly occurs in individuals with cancer. It is characterized by progressive weight loss, muscle wasting, and loss of appetite, despite adequate food intake. Cachexia is more prevalent in advanced stages of cancer and can significantly impact a patient's quality of life, treatment response, and overall prognosis. While the precise mechanisms underlying cancer cachexia are not entirely comprehended, its development is influenced by various factors. These factors include the release of pro-inflammatory cytokines (small proteins involved in cell signaling), metabolic changes induced by tumors, and the body's reaction to the presence of cancer cells. The diagnosis of cancer cachexia involves a medical history and physical examination, body weight and BMI, laboratory tests, and imaging tests. The treatment involves nutritional support, appetite stimulants, physical activity, and palliative care.
The increasing prevalence of cancer and cachexia, especially amongst the rising geriatric populations, is facilitating the demand for advanced therapeutic treatment and drugs, which in turn, is primarily driving the market growth. This is further supported by the increasing awareness amongst consumers regarding the availability of novel therapeutic drugs to treat cancer cachexia. Additionally, the shifting inclination of patients toward combinational therapies for improving lean body mass (LBM) through pharmacological, and non-pharmacological therapies and clinical trials is acting as another growth-inducing factor Moreover, significant technological advancements that are emphasizing on the development of effective medicines for cancer cachexia treatment are further propelling the market growth. Apart from this, the numerous favorable initiatives being undertaken by the government bodies of various countries and non-governmental organizations (NGOs) for sensitizing people regarding the causes of cancer cachexia, their symptoms, and the benefits of using advanced treatments are creating a positive outlook for the market.
IMARC Group's new report provides an exhaustive analysis of the cancer cachexia market in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets.
According to the report, the United States has the largest patient pool for cancer cachexia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cancer cachexia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cancer cachexia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cancer cachexia market
Reimbursement scenario in the market
In-market and pipeline drugs
Cancer Cachexia - In-Market and Pipeline Drugs
This report also provides a detailed analysis of the cancer cachexia disease marketed drugs and late-stage pipeline drugs.
In-cancer cachexia Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline cancer cachexia disease Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Regulatory Status
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the cancer cachexia market performed so far and how will it perform in the coming years?
What are the market shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cancer cachexia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cancer cachexia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cancer cachexia across the seven major markets?
What is the number of prevalent cases (2018-2034) of cancer cachexia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cancer cachexia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with cancer cachexia across the seven major markets?
What is the size of the cancer cachexia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cancer cachexia?
What will be the growth rate of patients across the seven major markets?
Cancer Cachexia: Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cancer cachexia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cancer cachexia market?
What are the key regulatory events related to the cancer cachexia market?
What is the structure of clinical trial landscape by status related to the cancer cachexia market?
What is the structure of clinical trial landscape by phase related to the cancer cachexia market?
What is the structure of clinical trial landscape by route of administration related to the cancer cachexia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CANCER CACHEXIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CANCER CACHEXIA - DISEASES OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CANCER CACHEXIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CANCER CACHEXIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management, and Treatment
8.2 Treatment Algorithm
9 CANCER CACHEXIA -UNMET NEEDS
10 CANCER CACHEXIA - KEY ENDPOINTS OF TREATMENT
11 CANCER CACHEXIA -MARKETED PRODUCTS
11.1 List of Cancer Cachexia -Marketed Drugs Across the Top 7 Markets
11.1.1 Anamorelin - Helsinn Therapeutics/Ono Pharmaceutical
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CANCER CACHEXIA - PIPELINE PRODUCTS
12.1 List of Cancer Cachexia Pipeline Drugs Across the Top 7 Markets
12.1 Ponsegromab - Pfizer
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.2 AV-380 - AVEO Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13 CANCER CACHEXIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 CANCER CACHEXIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CANCER CACHEXIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cancer Cachexia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cancer Cachexia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cancer Cachexia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cancer Cachexia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cancer Cachexia - Access and Reimbursement Overview
15.4 Market Scenario – Germany
15.4.1 Cancer Cachexia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cancer Cachexia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cancer Cachexia - Access and Reimbursement Overview
15.5 Market Scenario – France
15.5.1 Cancer Cachexia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cancer Cachexia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cancer Cachexia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cancer Cachexia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cancer Cachexia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cancer Cachexia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cancer Cachexia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cancer Cachexia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cancer Cachexia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cancer Cachexia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cancer Cachexia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cancer Cachexia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cancer Cachexia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cancer Cachexia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cancer Cachexia - Access and Reimbursement Overview
16 CANCER CACHEXIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CANCER CACHEXIA - MARKET- SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CANCER CACHEXIA – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CANCER CACHEXIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CANCER CACHEXIA - DISEASES OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CANCER CACHEXIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CANCER CACHEXIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management, and Treatment
8.2 Treatment Algorithm
9 CANCER CACHEXIA -UNMET NEEDS
10 CANCER CACHEXIA - KEY ENDPOINTS OF TREATMENT
11 CANCER CACHEXIA -MARKETED PRODUCTS
11.1 List of Cancer Cachexia -Marketed Drugs Across the Top 7 Markets
11.1.1 Anamorelin - Helsinn Therapeutics/Ono Pharmaceutical
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CANCER CACHEXIA - PIPELINE PRODUCTS
12.1 List of Cancer Cachexia Pipeline Drugs Across the Top 7 Markets
12.1 Ponsegromab - Pfizer
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.2 AV-380 - AVEO Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13 CANCER CACHEXIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 CANCER CACHEXIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CANCER CACHEXIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cancer Cachexia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cancer Cachexia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cancer Cachexia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cancer Cachexia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cancer Cachexia - Access and Reimbursement Overview
15.4 Market Scenario – Germany
15.4.1 Cancer Cachexia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cancer Cachexia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cancer Cachexia - Access and Reimbursement Overview
15.5 Market Scenario – France
15.5.1 Cancer Cachexia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cancer Cachexia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cancer Cachexia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cancer Cachexia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cancer Cachexia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cancer Cachexia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cancer Cachexia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cancer Cachexia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cancer Cachexia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cancer Cachexia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cancer Cachexia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cancer Cachexia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cancer Cachexia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cancer Cachexia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cancer Cachexia - Access and Reimbursement Overview
16 CANCER CACHEXIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CANCER CACHEXIA - MARKET- SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CANCER CACHEXIA – STRATEGIC RECOMMENDATIONS
19 APPENDIX
